“Everyone is on their own path. But no matter who you are, you shouldn’t have to go through it alone.”
KEITH
Veteran, grandfather, and actual PYLARIFY patient
Individual results may vary.
Many have found their way with PYLARIFY, the #1 utilized PSMA PET imaging agent for prostate cancer in the US. Watch two real stories about diagnosis, staging, recurrence, and finding a path forward.
Actual PYLARIFY patient
Watch Al’s story
“Whenever you’re dealing with a cancer diagnosis or cancer treatment, the more information you have, the more confident you are.”
Actual PYLARIFY patient
Watch Eric’s story
“PYLARIFY really helped me and my clinicians in terms of understanding what the next phases of treatment would be.”
Ongoing checkups and screenings are important steps you and your doctor can take to monitor prostate cancer. To help get a clearer image of the cancer and consider available treatment options, your doctor may discuss PSMA PET with PYLARIFY.
Questions to discuss with your doctor
Here are a few questions to help you start or continue the conversation with your doctor:
- Based on the initial diagnosis assessment, or if the prostate cancer has come back (recurred) or spread (metastasized), how can imaging options help determine the extent of the cancer?
- Is a PSMA PET scan with PYLARIFY an option for me?
- Can you talk to me about PET/CT scans and how safe they are?
The PYLARIFY Patient Brochure provides helpful information that includes:
- Facts about prostate cancer
- How PYLARIFY may help you and your doctor create an optimal treatment plan
- What to expect when getting a PYLARIFY scan
For understanding support
Coverage & Insurance
One-on-one guidance for understanding your plan and working through any possible coverage hurdles
Affordability
Personalized assistance with financial aid options that may help cover out-of-pocket costs for your scan
Education & Resources
Education, tools, and connection to advocacy groups that understand what you’re going through
Logistics Support
Ongoing support with choosing an imaging site, scheduling appointments, and finding transportation
APPROVED USE
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level.
PYLARIFY Injection is designed to detect prostate-specific membrane antigen (PSMA) positive lesions when used with PET imaging (scans).
IMPORTANT SAFETY INFORMATION
How well does PYLARIFY work?
- As with all diagnostic imaging tests such as X-rays, bone scans, and computed tomography (CT) scans, it is possible that the physician (a radiologist or nuclear medicine physician) who reviews your PYLARIFY PET/CT scan could interpret your results incorrectly. This means that a negative PYLARIFY PET/CT scan does not rule out that you have prostate cancer, and a positive PYLARIFY PET/CT scan does not confirm that you have prostate cancer.
- PYLARIFY seems to be affected by the amount (level) of PSA in your blood. As the levels of PSA in your blood go up, a PYLARIFY PET/CT scan is better able to identify prostate cancer.
Hypersensitivity reactions:
- Patients should be monitored for hypersensitivity reactions, especially those with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.
Radiation exposure:
- PYLARIFY is a radioactive diagnostic agent and adds to your long-term overall amount of radiation exposure, which could lead to an increased risk of cancer. You should stay well hydrated before, during, and after you are given PYLARIFY and urinate frequently to reduce radiation exposure.
What are the possible side effects of PYLARIFY?
- There were no serious reactions reported in patients who received scans in clinical trials with PYLARIFY, but some patients did report side effects associated with the use of PYLARIFY.
- The most commonly reported adverse reactions are headache, fatigue, and unusual taste in the mouth. An allergic reaction to PYLARIFY was reported in one patient with a significant history of allergic reactions.
Tell your doctor if you have any side effect that bothers you or does not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-888-INFO-FDA (1-888-463-6332).
Please read the accompanying full Prescribing Information.
APPROVED USE
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level.
PYLARIFY Injection is designed to detect prostate-specific membrane antigen (PSMA) positive lesions when used with PET imaging (scans).
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level.
PYLARIFY Injection is designed to detect prostate-specific membrane antigen (PSMA) positive lesions when used with PET imaging (scans).
IMPORTANT SAFETY INFORMATION
How well does PYLARIFY work?
- As with all diagnostic imaging tests such as X-rays, bone scans, and computed tomography (CT) scans, it is possible that the physician (a radiologist or nuclear medicine physician) who reviews your PYLARIFY PET/CT scan could interpret your results incorrectly. This means that a negative PYLARIFY PET/CT scan does not rule out that you have prostate cancer, and a positive PYLARIFY PET/CT scan does not confirm that you have prostate cancer.
- PYLARIFY seems to be affected by the amount (level) of PSA in your blood. As the levels of PSA in your blood go up, a PYLARIFY PET/CT scan is better able to identify prostate cancer.
Hypersensitivity reactions:
- Patients should be monitored for hypersensitivity reactions, especially those with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.
Radiation exposure:
- PYLARIFY is a radioactive diagnostic agent and adds to your long-term overall amount of radiation exposure, which could lead to an increased risk of cancer. You should stay well hydrated before, during, and after you are given PYLARIFY and urinate frequently to reduce radiation exposure.
What are the possible side effects of PYLARIFY?
- There were no serious reactions reported in patients who received scans in clinical trials with PYLARIFY, but some patients did report side effects associated with the use of PYLARIFY.
- The most commonly reported adverse reactions are headache, fatigue, and unusual taste in the mouth. An allergic reaction to PYLARIFY was reported in one patient with a significant history of allergic reactions.
Tell your doctor if you have any side effect that bothers you or does not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-888-INFO-FDA (1-888-463-6332).
Please read the accompanying full Prescribing Information.
How well does PYLARIFY work?
- As with all diagnostic imaging tests such as X-rays, bone scans, and computed tomography (CT) scans, it is possible that the physician (a radiologist or nuclear medicine physician) who reviews your PYLARIFY PET/CT scan could interpret your results incorrectly. This means that a negative PYLARIFY PET/CT scan does not rule out that you have prostate cancer, and a positive PYLARIFY PET/CT scan does not confirm that you have prostate cancer.
- PYLARIFY seems to be affected by the amount (level) of PSA in your blood. As the levels of PSA in your blood go up, a PYLARIFY PET/CT scan is better able to identify prostate cancer.
Hypersensitivity reactions:
- Patients should be monitored for hypersensitivity reactions, especially those with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.
Radiation exposure:
- PYLARIFY is a radioactive diagnostic agent and adds to your long-term overall amount of radiation exposure, which could lead to an increased risk of cancer. You should stay well hydrated before, during, and after you are given PYLARIFY and urinate frequently to reduce radiation exposure.
What are the possible side effects of PYLARIFY?
- There were no serious reactions reported in patients who received scans in clinical trials with PYLARIFY, but some patients did report side effects associated with the use of PYLARIFY.
- The most commonly reported adverse reactions are headache, fatigue, and unusual taste in the mouth. An allergic reaction to PYLARIFY was reported in one patient with a significant history of allergic reactions.
Tell your doctor if you have any side effect that bothers you or does not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-888-INFO-FDA (1-888-463-6332).
Please read the accompanying full Prescribing Information.